Author

A. Ianevski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Cancer Biology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:drug response / drug discovery· 7 Organism:human· 6 Research Focus:host-pathogen & immune response· 5 Approach:statistical model· 4 Research Focus:benchmarking· 2 Assay:bulk RNA-seq· 2 Organism:mouse· 2

Frequent Co-Authors

E. Zusinaite· 8 shared M. Bjoras· 8 shared V. Oksenych· 8 shared D. E. Kainov· 7 shared H. Lysvand· 6 shared T. Tenson· 6 shared M. P. Windisch· 5 shared R. Yao· 5 shared

Activity by Year

2019-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

E. Zusinaite

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

D. Pölöske, H. Sorger, A. Schönbichler, E. D. de Araujo, H. A. Neubauer, A. Orlova, S. H. Timonen, D. I. Abdallah, A. Ianevski, H. Kuusanmäki, M. Surbek, C. Wagner, T. Suske, M. L. Metzelder, M. Bergmann, , R. Moriggl

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

bioRxiv · Oct 12, 2023 · PreprintCancer Biology

Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness

A. Ianevski, R. Yao, R. M. Simonsen, V. Myhre, E. Ravlo, G. D. Kaynova, E. Zusinaite, J. M. White, Q. Pan, S. J. Polyak, V. Oksenych, M. P. Windisch, E. Lastauskiene, A. Vitkauskiene, A. Matukevicius, , D. E. Kainov

The paper develops scoring systems to predict novel broad-spectrum antivirals and combinations, aiming to improve preparedness for future viral outbreaks.

bioRxiv · Jan 15, 2022 · PreprintMicrobiology

Active components of commonly prescribed medicines affect influenza A virus-host cell interaction: a pilot study

A. Ianevski, R. Yao, E. Zusinaite, H. Lysvand, V. Oksenych, T. Tenson, M. Bjoras, D. E. Kainov

This study examines how active components of commonly prescribed medicines affect influenza A virus-host cell interactions both in silico and in vitro.

bioRxiv · Jul 11, 2021Pharmacology & Toxicology

Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo

A. Ianevski, R. Yo, H. Lysvand, G. Grodeland, N. Legrand, V. Oksenych, E. Zusinaite, T. Tenson, M. Bjoras, D. E. Kainov

This study combines nafamostat and interferon-alpha to suppress SARS-CoV-2 infection by targeting TMPRSS2 in vitro and in vivo.

bioRxiv · Jun 16, 2021Microbiology

Interferon alpha-based combinations suppress SARS-CoV-2 infection in vitro and in vivo

A. Ianevski, R. Yao, E. Zusinaite, L. S. Lello, S. Wang, E. Jo, J. Yang, E. Ravlo, W. Wang, H. Lysvand, K. Loseth, V. Oksenych, T. Tenson, M. P. Windisch, M. Poranen, , D. E. Kainov

This study shows that IFNa-based combinations effectively inhibit SARS-CoV-2 infection in vitro and in vivo, with synergistic effects against other viruses.

bioRxiv · Jan 5, 2021 · PreprintMicrobiology

Identification of novel antiviral drug combinations in vitro and tracking their development

A. Ianevski, R. Yao, S. Biza, E. Zusinaite, A. Mannik, G. Kivi, A. Planken, K. Kurg, E.-M. Tombak, M. Ustav, N. Shtaida, E. Kulesskiy, E. Jo, J. Yang, H. Lysvand, , D. E. Kainov

This study identifies novel synergistic antiviral drug combinations effective against SARS-CoV-2, echovirus 1, HCV, and HIV-1 in vitro and provides an online resource for their developmental status.

bioRxiv · Sep 17, 2020 · PreprintMicrobiology

Potential antiviral options against SARS-CoV-2 infection

A. Ianevski, R. Yao, M. H. Fenstad, S. Biza, E. Zusinaite, H. Lysvand, K. Loeseth, V. M. Lamndsem, J. F. Malmring, V. Oksenych, S. E. Erlandsen, P. A. Aas, L. Hagen, C. H. Pettersen, J. E. Afset, , D. E. Kainov

The paper identifies potent convalescent sera and broad-spectrum antivirals effective against SARS-CoV-2 using a neutralization assay and cell culture screening.

bioRxiv · May 12, 2020Microbiology

Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19

M. Ko, S. Y. Chang, S. Y. Byun, A. Ianevski, I. Choi, A. L. P. H. d'Alexandry d'Orengiani, D. Kainov, D. Shum, J.-Y. Min, M. P. Windisch

The paper screens FDA-approved drugs against a MERS-CoV isolate to identify potential therapies for COVID-19, finding several drugs with therapeutic indexes >6 and synergistic combinations.

bioRxiv · Feb 25, 2020Microbiology

Chemical, physical and biological triggers of Bcl-xL-mediated apoptosis

A. Ianevski, E. Kulesskiy, K. Krpina, G. Lou, Y. Aman, A. Bugai, K. Aasumets, Y. Akimov, D. Bulanova, K. Gildemann, A. F. Arutyunyan, O. Y. Susova, A. L. Zhuze, P. Ji, W. Wang, , D. E. Kainov

This study shows that Bcl-xL-specific inhibitors, when combined with DNA-damaging agents or physical insults, trigger apoptosis in various cell types and C. elegans by releasing Bad and Bax from Bcl-xL.

bioRxiv · Jan 13, 2020Cancer Biology

Critical Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis

K. Bosl, A. Ianevski, T. T. Than, P. I. Andersen, S. Kuivanen, M. Teppor, E. Zusinaite, U. Dumpis, A. Vitkauskiene, R. J. Cox, H. Kallio-Kokko, A. Bergqvist, T. Tenson, V. Oksenych, M. Bjoras, , R. K. Kandasamy

This study identifies critical host-virus interaction nodes through network analysis and drug re-purposing, revealing key targets for antiviral therapies.

bioRxiv · Feb 13, 2019 · PreprintImmunology